Suppr超能文献

在人髓细胞存在的情况下生成嵌合抗原受体(CAR)T细胞。

generation of CAR T cells in the presence of human myeloid cells.

作者信息

Ho Naphang, Agarwal Shiwani, Milani Michela, Cantore Alessio, Buchholz Christian J, Thalheimer Frederic B

机构信息

Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Paul-Ehrlich-Straße 51-59, 63225 Langen, Germany.

Frankfurt Cancer Institute, Goethe University, 60590 Frankfurt am Main, Germany.

出版信息

Mol Ther Methods Clin Dev. 2022 Jun 9;26:144-156. doi: 10.1016/j.omtm.2022.06.004. eCollection 2022 Sep 8.

Abstract

Pre-clinical humanized mouse models are a powerful tool to evaluate immunotherapies. NSG-SGM3 mice reconstituted with human stem cells (huSGM3) develop pronounced human myeloid cells due to transgenic expression of stem cell factor, granulocyte-macrophage colony-stimulating factor, and interleukin-3 (IL-3) compared with the widely used humanized NSG (huNSG) model. We assessed generation of CD19-CAR T cells in huSGM3 mice upon single intravenous injection of the T cell-specific lentiviral vectors (LVs) CD4-LV and CD8-LV. While CAR T cell generation was clearly detectable in individual mice, generation appeared less efficient than previously observed for huNSG mice. Especially for the CD4-LV group, this correlated with increased IL-15 and decreased GM-CSF levels, indicating activation of monocytes and macrophages. Co-culture assays identified macrophages as a potential barrier for gene transfer. Refining CD4-LV and CD8-LV with a less immunogenic surface by using modified packaging cells substantially improved the transduction of lymphocytes in the presence of macrophages, as well in huSGM3 mice. Notably, two mice that developed less CAR T cells showed high interferon-α or -β levels before vector injection. Our data emphasize the relevance of innate immune responses for generation of CAR T cells, which can be overcome by vector surface engineering.

摘要

临床前的人源化小鼠模型是评估免疫疗法的有力工具。与广泛使用的人源化NSG(huNSG)模型相比,用人干细胞重建的NSG-SGM3小鼠(huSGM3)由于干细胞因子、粒细胞-巨噬细胞集落刺激因子和白细胞介素-3(IL-3)的转基因表达而发育出明显的人髓系细胞。我们评估了在单次静脉注射T细胞特异性慢病毒载体(LVs)CD4-LV和CD8-LV后,huSGM3小鼠中CD19嵌合抗原受体(CAR)T细胞的产生情况。虽然在个别小鼠中可明显检测到CAR T细胞的产生,但产生效率似乎低于先前在huNSG小鼠中观察到的情况。特别是对于CD4-LV组,这与IL-15水平升高和GM-CSF水平降低相关,表明单核细胞和巨噬细胞被激活。共培养试验确定巨噬细胞是基因转移的潜在障碍。通过使用修饰的包装细胞来优化具有较低免疫原性表面的CD4-LV和CD8-LV,在存在巨噬细胞的情况下以及在huSGM3小鼠中,显著提高了淋巴细胞的转导效率。值得注意的是,两只产生较少CAR T细胞的小鼠在载体注射前显示出高干扰素-α或-β水平。我们的数据强调了先天免疫反应对CAR T细胞产生的相关性,这可以通过载体表面工程来克服。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cd1/9249670/a84354b57163/fx1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验